Corticotropin-releasing factor (CRF) and α2 adrenergic receptors mediate heroin withdrawal-potentiated startle in rats

International Journal of Neuropsychopharmacology

Volumn 16, Issue 8, 2013, Pages 1867-1875

  Park, Paula E ^a,b   Vendruscolo, Leandro F ^a   Schlosburg, Joel E ^a   Edwards, Scott ^a   Schulteis, Gery ^c   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c University of California   (United States)

Author keywords

Acoustic startle response; Acute heroin withdrawal; Brain stress system

Indexed keywords

CLONIDINE; DIAMORPHINE; HORMONE RECEPTOR BLOCKING AGENT; N,N BIS(2 METHOXYETHYL) 3 (4 METHOXY 2 METHYLPHENYL) 2,5 DIMETHYL PYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; NORADRENALIN; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; HEROIN DEPENDENCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STARTLE REFLEX;

ACOUSTIC STIMULATION; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; CLONIDINE; CONDITIONING, OPERANT; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; HEROIN; MALE; NARCOTICS; NOREPINEPHRINE; PSYCHOACOUSTICS; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-2; SELF ADMINISTRATION; STARTLE REACTION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; YOHIMBINE;

EID: 84882955776     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000308     Document Type: Article

References (37)

1. Aston-Jones G, Delfs JM, Druhan J, Zhu Y (1999) The bed nucleus of the stria terminalis. A target site for noradrenergic actions in opiate withdrawal. Ann N Y Acad Sci 877: 486-498.
2. Contarino A, Papaleo F (2005) The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc Natl Acad Sci USA 102: 18649-18654.
3. Davis M, Falls WA, Campeau S, Kim M (1993) Fear-potentiated startle: a neural and pharmacological analysis. Behav Brain Res 58: 175-198.
4. Edwards S, Graham DL, Whisler KN, Self DW (2009) Phosphorylation of GluR1, ERK, and CREB during spontaneous withdrawal from chronic heroin selfadministration. Synapse 63: 224-235.
5. Edwards S, Vendruscolo LF, Schlosburg JE, Misra KK, Wee S, Park PE, Schulteis G, Koob GF (2012) Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF(1) receptor antagonism. Neuropharmacology 62: 1142-1151.
6. Fatseas M, Denis C, Lavie E, Auriacombe M (2010) Relationship between anxiety disorders and opiate dependence-a systematic review of the literature: implications for diagnosis and treatment. J Subst Abuse Treat 38: 220-230.
7. Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF (2007) Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 61: 78-86.
8. Gossop M (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21: 253-259.
9. Greenwell TN, Funk CK, Cottone P, Richardson HN, Chen SA, Rice KC, Zorrilla EP, Koob GF (2009) Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats. Addict Biol 14: 130-143.
10. Harris AC, Gewirtz JC (2004) Elevated startle during withdrawal from acute morphine: a model of opiate withdrawal and anxiety. Psychopharmacology (Berl) 171: 140-147.
11. Harris GC, Aston-Jones G (1993) Beta-adrenergic antagonists attenuate withdrawal anxiety in cocaine- and morphine-dependent rats. Psychopharmacology (Berl) 113: 131-136.
12. Helton DR, Modlin DL, Tizzano JP, Rasmussen K (1993) Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity. Psychopharmacology (Berl) 113: 205-210.
13. Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R (2001) The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13: 373-380.
14. Kehne JH, Davis M (1985) Central noradrenergic involvement in yohimbine excitation of acoustic startle: effects of DSP4 and 6-OHDA. Brain Res 330: 31-41.
15. Koob GF (1999) Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 46: 1167-1180.
16. Koob GF (2008) A role for brain stress systems in addiction. Neuron 59: 11-34.
17. Koob GF, Le Moal M (2005) Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci 8: 1442-1444.
18. Koob GF, Le Moal M (2008) Addiction and the brain antireward system. Annu Rev Psychol 59: 29-53.
19. Lee Y, Davis M (1997) Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J Neurosci 17: 6434-6446.
20. Maldonado R (1997) Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev 21: 91-104.
21. Rasmussen K, Helton DR, Berger JE, Scearce E (1994) The CCK-B antagonist LY288513 blocks diazepam-withdrawal-induced increases in auditory startle response. Ann N Y Acad Sci 713: 374-376.
22. Rassnick S, Koob GF, Geyer MA (1992) Responding to acoustic startle during chronic ethanol intoxication and withdrawal. Psychopharmacology (Berl) 106: 351-358.
23. Richardson HN, Zhao Y, Fekete EM, Funk CK, Wirsching P, Janda KD, Zorrilla EP, Koob GF (2008) MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol Biochem Behav 88: 497-510.
24. Risbrough VB, Hauger RL, Pelleymounter MA, Geyer MA (2003) Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) 170: 178-187.
25. Rothwell PE, Thomas MJ, Gewirtz JC (2012) Protracted manifestations of acute dependence after a single morphine exposure. Psychopharmacology (Berl) 219: 991-998.
26. Schulteis G, Yackey M, Risbrough V, Koob GF (1998a) Anxiogenic-like effects of spontaneous and naloxoneprecipitated opiate withdrawal in the elevated plus-maze. Pharmacol Biochem Behav 60: 727-731.
27. Schulteis G, Stinus L, Risbrough VB, Koob GF (1998b) Clonidine blocks acquisition but not expression of conditioned opiate withdrawal in rats. Neuropsychopharmacology 19: 406-416.
28. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20: 1093-1102.
29. Smith RJ, Aston-Jones G (2008) Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct 213: 43-61.
30. Specio SE, Wee S, O'Dell LE, Boutrel B, Zorrilla EP, Koob GF (2008) CRF(1) receptor antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology (Berl) 196: 473-482.
31. Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W, Koob GF (1996) Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 273: 1561-1564.
32. Swerdlow NR, Geyer MA, Vale WW, Koob GF (1986) Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berl) 88: 147-152.
33. Swerdlow NR, Britton KT, Koob GF (1989) Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharmacology 2: 285-292.
34. Valentino RJ, Van Bockstaele E (2001) Opposing regulation of the locus coeruleus by corticotropin-releasing factor and opioids. Potential for reciprocal interactions between stress and opioid sensitivity. Psychopharmacology (Berl) 158: 331-342.
35. Vendruscolo LF, Schlosburg JE, Misra KK, Chen SA, Greenwell TN, Koob GF (2011) Escalation patterns of varying periods of heroin access. Pharmacol Biochem Behav 98: 570-574.
36. Zhang Z, Schulteis G (2008) Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behavior in the elevated plus maze. Pharmacol Biochem Behav 89: 392-403.
37. Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A (2002) Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952: 188-199.